Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

• Verfasst von: Sznol, Mario [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Titel: Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
• Verf.angabe: M. Sznol, P.F. Ferrucci, D. Hogg, M. Atkins, P. Wolter, M. Guidoboni, C. Lebbe, J. Kirkwood, J. Schachter, G. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, J. Jiang, F.S. Hodi, J. Wolchok
• Fussnoten: Gesehen am 14.11.2017
• Titel Quelle: Enthalten in: Annals of oncology
• Jahr Quelle: 2016
• Band/Heft Quelle: 27(2016,Supplement 6) Artikel-Nummer 1123P, 1 Seite
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdw379.18
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 156533860X

Abstract

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [e-mail]: Cumulative data indicate greater tumor response from the addition of IPI (anti-CTLA-4 antibody) to NIVO (anti-PD-1 antibody) in MEL pts, but with a higher frequency of adverse events (AEs) than observed with either agent alone. The objective of this pooled analysis is to describe the safety profile of NIVO + IPI across MEL studies in which established guidelines for AE management were utilized.Methods: A retrospective safety review was conducted for three phase 1-3 trials in which all MEL pts who received at least 1 dose of the standard regimen, NIVO 1 mg/kg + IPI 3 mg/kg Q3W x 4, then NIVO 3 mg/kg Q2W until disease progression or unacceptable toxicity. Analyses included AEs, select (immune-related) AEs, time to onset and resolution, use...